# The Infected Blood Compensation Scheme Regulations 2025, Paragraph 3: Neurological conditions resulting in long-term severe physical disability


(1) A person (“P”) is to be treated as having a neurological condition resulting in long-term severe physical disability if—
(a) P has—
(i) HIV and has been diagnosed with any of the conditions listed in sub-paragraph (2);
(ii) a Hepatitis B infection of severity level 2, 3 or 4 and has been diagnosed with any of the conditions listed in sub-paragraph (3);
(iii) a Hepatitis C infection of severity level 2, 3 or 4 and has been diagnosed with any of the conditions listed in sub-paragraph (4), and
(b) P has been assessed as needing at least level 2 care as a result of the diagnosed condition.
(2) The conditions referred to in sub-paragraph (1)(a)(i) are—
(a) any of the following conditions, if the condition is secondary to advanced HIV disease and neoplasia secondary to that disease—
(i) cerebral toxoplasmosis;
(ii) central nervous system tuberculosis;
(iii) cytomegalovirus encephalitis;
(iv) varicella zoster virus encephalitis;
(v) herpes simplex virus encephalitis;
(vi) Epstein Barr virus encephalitis;
(vii) progressive multifocal leucoencephalopathy;
(viii) cryptococcal meningitis;
(ix) primary central nervous system lymphoma;
(x) thromboembolic disease secondary to bacterial or fungal endocarditis;
(b) any of the following conditions, secondary to, or associated with, HIV infection—
(i) HIV vacuolar myelopathy;
(ii) transverse myelitis;
(iii) thrombotic thrombocytopenic purpura;
(iv) cerebrovascular ischaemic or haemorrhagic stroke;
(v) coagulopathies: Antiphospholipid syndrome;
(vi) chronic inflammatory demyelinating polyneuropathy;
(vii) cytomegalovirus polyradiculopathy;
(viii) HIV myopathy.
(3) The conditions referred to in sub-paragraph (1)(a)(ii) are—
(a) peripheral neuropathy caused by mixed cryoglobulinaemic vasculitis that results in mobility disability;
(b) peripheral neuropathy occurring in the context of Hepatitis B-associated polyarteritis nodosa that results in mobility disability.
(4) The conditions referred to in sub-paragraph (1)(a)(iii) are—
(a) cryoglobulinaemic vasculitis induced neurological disease that results in mobility disability;
(b) peripheral neuropathy caused by mixed cryoglobulinaemic vasculitis that results in mobility disability.

---
Source: https://www.legislation.gov.uk/ukdsi/2025/9780348268843/schedule/2/paragraph/3 (the official version)
Page: https://openlegislation.uk/draft-infected-blood-compensation-scheme-regulations-2025/schedule-2/paragraph-3
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.